Exhibit 10.1
*** Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 CFR §§240.24b-2
2013 Corporate Goals for Strategic Leadership Team
Approved by the Compensation Committee on April 29, 2013
Revenue and Operating Income (50)%
Revenues for the Year - 20%
Interpolation will be used.
Total Revenue Growth Vs. Prior Year
 
Funding
*Corresponding Unit Growth Rate
≥ [***]% growth
 
200%
[***]
≥ [***]% growth
 
175%
[***]
≥ [***]% growth
 
150%
[***]
≥ [***]% ([***])
 
125%
[***]
≥ [***]% growth
 
100%
[***]
≥ [***]% growth
 
75%
[***]
≥ [***]% growth
 
50%
[***]
≥ [***]% growth
 
25%
[***]
< [***]% growth
 
No Payout
 

  * reference only not calculated in the funding

Q4 Revenue Implications - 20%
Interpolation will be used.

• Q4 2013 growth over Q4 2012 - $13.6 million
Q4 Total Revenue Growth Vs. Prior Year
 
Funding
Q4 Revenues
≥ [***]% growth
 
200%
[***]
≥ [***]% growth
 
175%
[***]
≥ [***]% growth
 
150%
[***]
≥ [***]% growth
 
125%
[***]
≥ [***]% growth
 
100%
[***]
≥ [***]% growth
 
75%
[***]
< [***]% growth
 
No Payout
 

--------------------------------------------------------------------------------

Operating Income (millions) - 10%
Interpolation will be used.
Operating Income (Loss) [***]
 
Operating Loss +/-
Funding
([***])
 
60%
200%
([***])
 
70%
175%
([***])
 
80%
150%
([***])
 
90%
125%
([***]) target [***]
 
100%
100%
([***])
 
110%
75%
([***])
 
120%
50%
([***])
 
130%
25%
([***])
 
140%
No Payout

Managed Care (30%)
• 2 Commercial Plans (> [***] million lives in total) - 20%
○ +5% payout for each additional plan having > [***] million lives
○ e.g., 3 plans = 25% payout
• 8 Employer Conversions (> [***] lives each) - 5%
• 1 Major National Plan Win (or very high likelihood of coverage in the new
year) - 5%
○ +5% if delivered by end of [***] (e.g., 10% payout)
○ +10% if delivered by end of [***] (e.g., 15% payout)
HDL-P (10%)
• FDA Clearance by the end of Q4
Compliance & Ethics (10%)
• 5% - meet the timely completion requirements of Sunshine Act
• 5% - no significant deficiency re: Adva Med Policy

[***]    Certain confidential information in this document, marked by bracketed
asterisks, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 promulgated under the Securities
Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.